Raphael Pharmaceutical Inc.
RAPH· OTC
RAPHRaphael Pharmaceutical Inc.
Filed May 14, 2026 · 10-Q · 44 days after period end · 0001213900-26-056181
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$229.00K | -$429.00K | -$550.00K | -$264.00K |
| EPS Diluted | $0.01 | $0.02 | $0.03 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Raphael Pharmaceutical Inc. · CIK 1415397 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end
